Codexis announces the publication of research demonstrating

Collaboration with Merck published in Science magazine

REDWOOD CITY, Calif., June 17, 2022 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announces publication with Merck, known as MSD’s name outside of the United States and Canada, from an article in the peer-reviewed journal Sciencedetailing the development of a suite of enzymes and their application for the site-selective synthesis of insulin bioconjugates.

“Our ongoing agreement with Merck has produced multiple scientific breakthroughs in the field of enzyme engineering. This work described in Science is another great example of how scientific collaboration can effectively address the challenges facing the biotech industry,” said John Nicols, President and CEO of Codexis. “The development of this enzyme toolkit opens up opportunities to generate new clinical leads that were not possible before.”

The publication describes enzyme development and optimization using Codexis’ proprietary CodeEvolver® technology platform. Each enzyme has a unique specificity and has been evaluated for its ability to modify insulin. The work described highlights how enzymes can be engineered to functionalize peptides in targeted ways beyond what is possible with conventional chemical approaches.

“The ability to specifically target chemical moieties along a peptide chain opens up many possibilities for future protein modification,” said Ania Fryszkowska, Ph.D., Director, Biocatalysis, Enabling Technologies, Merck Research Laboratories and an author correspondent of the publication.

About Codexis

Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel high-performance enzymes and biotherapeutics. Codexis enzymes have applications in the sustainable manufacturing of pharmaceutical, food and industrial products; in creating the next generation of life science tools; and as gene therapy and oral enzyme therapies. The company’s unique performance enzymes drive improvements such as: reduced energy consumption, waste generation and capital requirements; higher yields; more accurate diagnoses; and more effective therapies. Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet. For more information, visit

Forward-looking statements

To the extent that the statements in this press release are not descriptions of historical facts about Codexis, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You should not place undue reliance on these forward-looking statements as they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the control of Codexis and which could materially affect actual results. Additional information about factors that could materially affect actual results is available in Codexis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 28, 2022, including under “Risk Factors,” in Codexis’ Quarterly Report on Form 10-Q filed with the SEC on May 9, 2022, and in Codexis’ other periodic reports filed with the SEC. Codexis expressly disclaims any intention or obligation to update these forward-looking statements, except as required by law.

Contact with Investor Relations:

Slang Partners
Brendan Strong/Carrie McKim
(212) 600-1902
[email protected]

Jacob L. Thornton